Can investors afford to wait for zomedica stock to take off?
Dec 20, 2021 · According to the new TipRanks’ Risk Factors tool, Zomedica stock is at risk mainly from three factors: Finance and Corporate, Production, and Ability to …
Is zomedica Pharmaceuticals Corp (ZMD) a buy or sell?
Apr 11, 2022 · Zomedica Pharmaceuticals Corp stock price down 3.82% on Monday(Updated on Apr 11, 2022) Sell candidate since 2022-04-08 Loss -3.82% PDF. The Zomedica Pharmaceuticals Corp stock price fell by -3.82% on the last day (Monday, 11th Apr 2022) from $0.31 to $0.30. During the day the stock fluctuated 2.99% from a day low at $0.30 to a day high of $0.31.
What does zomedica do?
Jul 19, 2021 · Zomedica’s Truforma platform, which produces diagnostic results on the spot, went on sale in Mar. 2021. Its sales are still minimal (just over $14,000 in the first quarter) as the company works on...
Is Zom a buy or sell in 2020?
Feb 17, 2022 · Zomedica provide the veterinary sector with innovative treatments. Working closely with vets and scientists, Zomedica are able to offer a high standard of service and produce products of a superior quality. In order to ensure the continued supply of high-quality medication for pets worldwide, Zomedica work together with licensed pharmaceutical ...
Should I hold or sell Zomedica stock?
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Zomedica Pharmaceuticals Corp is 'Strong Sell'.
Is Zomedica stock expected to go up?
Stock Price Forecast The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20. The median estimate represents a +319.14% increase from the last price of 0.29.
Will Zomedica go up tomorrow?
Tomorrow's movement Prediction of Zomedica Pharmaceuticals Corp ZOM as on 08 Apr 2022 appears strongly Bullish. This stock started moving upwards as soon as it opened....Munafa value: 55 as on 08 Fri Apr 2022.Upside target0.33Upside target0.31Downside target0.3Downside target0.291 more row
Will Zomedica stock go up in 2022?
Target values for the price of one Zomedica share for Nov 2022. The weighted average target price per Zomedica share in Nov 2022 is: 0.29. In Nov, the positive dynamics for Momo shares will prevail with possible monthly volatility of 17.333% volatility is expected.Apr 11, 2022
Is Zomedica undervalued?
InvestorPlace's Mark Hake estimates Zomedica (NYSEAMERICAN:ZOM) is worth between $1.11 and $1.61 a share. That makes ZOM stock a buy at current prices.Jun 28, 2021
What is Zomedica target price?
Stock Price TargetsHigh$1.20Median$1.20Low$1.20Average$1.20Current Price$0.35
Why is ZOM dropping?
CEO Robert Cohen said the move was precipitated by "changes at our current distributor that we believe have impacted its ability to market our products effectively." Those words likely startled investors, many of whom decided to sell their shares. Zomedica's stock price dropped sharply on Thursday.Apr 15, 2021
Is TherapeuticsMD a good stock to buy?
TherapeuticsMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Who is on Zomedica's Insider Roster?
The list of insiders at Zomedica includes Ann Marie Cotter, Christopher Ross Macleod, Johnny D Powers, Robert Cohen, and Stephanie Morley. Learn m...
What percentage of Zomedica stock is owned by insiders?
1.99% of Zomedica stock is owned by insiders. Learn more on ZOM's insider holdings.
Which Zomedica insiders have been buying company stock?
The following insider purchased Zomedica stock in the last 24 months: Johnny D Powers ($212,500.00).
How much insider buying is happening at Zomedica?
Insiders have purchased a total of 875,000 Zomedica shares in the last 24 months for a total of $212,500.00 bought.
Which Zomedica insiders have been selling company stock?
The following insiders have sold Zomedica stock in the last 24 months: Ann Marie Cotter ($88,275.76), Christopher Ross Macleod ($7,040.00), Johnny...
How much insider selling is happening at Zomedica?
Insiders have sold a total of 5,626,676 Zomedica shares in the last 24 months for a total of $5,145,678.26 sold.
Signals & Forecast
Support, Risk & Stop-loss
The Zomedica Pharmaceuticals Corp stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock.
Is Zomedica Pharmaceuticals Corp stock A Buy?
Zomedica Pharmaceuticals Corp finds support from accumulated volume at $0.58 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Why is ZOM stock dropping?
Zomedica Pharmaceuticals Corp holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
Will Zomedica (ZOM) stock go back up?
Zomedica shares have fallen more than 30 percent in the past month and 80 percent from their Feb. 2021 peak. Zomedica stock’s decline can be linked to some investors getting frustrated with delays in ramping up Truforma platform sales.
Zomedica's (ZOM) stock price forecast
In its latest corporate update, Zomedica implied that setting up the internal sales force for Truforma is progressing well and sales should begin to materialize soon. It said it expects to close the year with 15 sales representatives, and other industry professionals will support the team.
Zomedica's FDA approval
Wall Street analysts' average price target of $1.20 for ZOM suggests the stock could rise more than 90 percent in the next 12 months.
Should you buy or sell Zomedica (ZOM) stock?
Zomedica’s Truforma platform, which produces diagnostic results on the spot, went on sale in Mar. 2021. Its sales are still minimal (just over $14,000 in the first quarter) as the company works on the internal marketing team.
Who is on Zomedica's Insider Roster?
Penny stocks require extra caution, and Zomedica stock is no exception. But ZOM looks like it could pay off well for patient investors—at about 80 percent below its peak, it could be a good deal.
Which Zomedica insiders have been buying company stock?
The list of insiders at Zomedica includes Ann Marie Cotter, Christopher Ross Macleod, Johnny D Powers, Robert Cohen, and Stephanie Morley. Learn more#N#on ZOM's insiders
How much insider buying is happening at Zomedica?
The following insider purchased Zomedica stock in the last 24 months: Johnny D Powers ($100,000.00).
Which Zomedica insiders have been selling company stock?
Insiders have purchased a total of 625,000 Zomedica shares in the last 24 months for a total of $100,000.00 bought.
How much insider selling is happening at Zomedica?
The following insiders have sold Zomedica stock in the last 24 months: Ann Marie Cotter ($88,275.76), Christopher Ross Macleod ($7,040.00), Johnny D Powers ($870,000.00), Robert Cohen ($3,032,812.50), and Stephanie Morley ($933,800.00).
Who recommended Dogecoin before it soared?
Insiders have sold a total of 5,626,676 Zomedica shares in the last 24 months for a total of $5,145,678.26 sold.
Who is Dana Blankenhorn?
Thomas Yeung is an expert when it comes to finding fast-paced growth opportunities on Reddit. He recommended Dogecoin before it skyrocketed over 8,000%, Ripple before it flew up more than 480% and Cardano before it soared 460%. Now, in a new report, he’s naming 17 of his favorite Reddit penny stocks.
Who is the star of Tiger King?
Dana Blankenhorn has been a financial journalist since 1978. His latest book is Technology’s Big Bang: Yesterday, Today and Tomorrow with Moore’s Law, essays on technology available at the Amazon Kindle store. Follow him on Twitter at @danablankenhorn. Article printed from InvestorPlace Media, ...
What is Zomedica Pharmaceuticals?
Zomedica has also made some mistakes along the way. The biggest pitfall may have been getting Tiger King star Carole Baskin to issue a video endorsement early this year. If this were a consumer sale that might have made sense. But Baskin’s celebrity was likely a turnoff to vets.
What is value scorecard?
Zomedica Corp. is a veterinary health company. It creates products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica Corp., formerly known as Zomedica Pharmaceuticals Corp., is based in Ann Arbor, Michigan.
What is a truforma?
The Value Scorecard identifies the stocks most likely to outperform based on its valuation metrics. This list of both classic and unconventional valuation items helps separate which stocks are overvalued, rightly lowly valued, and temporarily undervalued which are poised to move higher.
Is Zomedica profitable?
Truforma is a diagnostic platform that can tell vets several key pieces of information about the health of their feline and canine patients. In particular, it can detect a pet's level of cortisol, thyroid stimulating hormone (TSH), and free T4 (thyroxine), depending on which test the practitioner chooses. The system has two main components: the Truforma analyzer machine itself, and the test cassettes that vets load with biological samples from Fido. Then, the vet pops the cassette into the device, and it delivers a readout shortly after.